Charles Koch The same devout libertarian known for spending a fortune on political causes is now being the same actively funding efforts to end federal marijuana prohibition.
Here’s why pro-pot advocates in both parties are high on his support.
Soon, Koch might be known as the billionaire who persuaded Republican and Democratic holdouts to legalize cannabis at the federal level.
“2022, Will Be Our Year To Watch For Legalization Interests To Grow” – Steven Smith, 1st Hemp USA News
Koch admits that he is not on the front lines fighting for legalization—Brian Hooks, the CEO of Stand Together (which Koch founded) and Koch Industries’ former longtime general counsel Mark Holden, and others, are doing the boots-on-the-ground work.
It may come as some surprise to discover that Koch is an advocate of legalization, especially since the billionaire has already spent a fortune backing Republican politicians and lobbying for conservative legislation. Koch is a diehard libertarian, though, and fully opposes the idea that the government could lock someone away in jail just for smoking a joint or otherwise enjoying their own personal freedom.
“It should be the individual’s choice,” Koch said: ‘this’ is counterproductive. It ruins people’s lives, creates conflict in society and is anti-progress. The whole thing never made sense to me… Marijuana, as I understand it, is less addictive than alcohol.
However, it’s unclear whether the long-awaited federal legalization bill, a draft of which Sens. Chuck Schumer, Cory Booker and Ron Wyden introduced in July, can get the 10 Republican senators and all 50 Democratic senators needed to pass it. Schumer readily admits he doesn’t yet have the numbers and President Biden does not support legalization. For politicians on both sides of the aisle who still oppose cannabis, Koch has two questions:
“If you don’t like marijuana, or don’t like people doing that, and you have all these laws, how’s that working out for you?” he asks, before making his second point: “Marijuana, as I understand it, is less addictive than alcohol. So why is alcohol legal and marijuana isn’t?”
Koch admits that he is not on the front lines fighting for legalization—Brian Hooks, the CEO of Stand Together (which Koch founded) and Koch Industries’ former longtime general counsel Mark Holden, and others, are doing the boots-on-the-ground work.
1st Hemp USA News is a resource of Inspirational Technologies (2021)Inspirational Technologies (2021) AllRightsReservedYOUR ONE STOP BLOG FOR INFORMATION EDUCATION INSPIRATION OF ESSENTIAL INNOVATION RENOVATION – THANK YOU FOR YOUR INTEREST
*This site receives compensation for referred sales of some or all mentioned products.
At the U.S. Food and Drug Administration, we see these knowledge gaps as an opportunity to develop new ways of building the science to inform public health decisions. The FDA evaluates CBD just like any other substance we regulate, under a regulatory framework defined by law and with rigorous scientific evidence as a basis for both our regulatory approach and information we communicate. We’ve consistently communicated concerns and questions regarding the science, safety, and quality of many of these products based on currently available evidence. We still don’t have clear answers to important questions such as what adverse reactions may be associated with CBD products and what risks are associated with the long-term use of CBD products.
Better data in these areas are needed for the FDA and other public health agencies to make informed, science-based decisions that impact public health. We see an important public health opportunity in using novel sources of data and rigorous analytical methods to build a more robust base of scientific evidence on the safety profile and use of CBD products.
Inspirational Technologies “4 Hemp Club” promotes Hemp for Agriculture
As we continue to evaluate the regulatory frameworks that apply to certain cannabis-derived products that are intended for non-drug uses, including whether any new FDA regulations may be warranted, the FDA continues to work actively with drug developers through the investigational new drug, drug review, and drug approval processes. The FDA’s work in this area involves both meetings with drug developers to provide advice that is specific to the development of a proposed product, as well as the development of guidance documents on high-priority regulatory and scientific issues. For example, the FDA recently published a draft guidance “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research,” which, when final, will represent the agency’s current thinking on sources of cannabis, resources for information on quality considerations, and percent delta-9 THC calculation.
The FDA is evaluating comments submitted to the agency regarding this draft guidance. FDA’s CBD Product Sampling and Testing Activities Sampling and testing of marketed CBD products is another way that the FDA has gathered more information about the safety profile of these products. This is an important component of the FDA’s work because little is known about the amounts of CBD and various related cannabinoids, as well as the occurrence of toxic elements, pesticides, other possible chemical contaminants, and adulterants, that may be present in CBD products that are marketed to consumers.
The FDA made the results of such testing publicly available. The FDA also designed surveys of the market and currently is conducting a two-phase marketplace sampling and testing study.
The first phase involved a small sampling and analysis study (~200 samples) conducted by the agency. While the data collected so far are from a limited sample size and are insufficient to draw definitive conclusions regarding the prevalence of results in marketed products, general observations indicate fewer than half of the tested products which presented label claims contained CBD at concentrations within 20% of their claimed amount and some products contained the psychoactive, intoxicating cannabinoid THC. The FDA has recently published findings from this work.
We are currently working with a third party on conducting the second phase of the sampling plan that will involve a much larger sample set (1000-3000) that includes collection of CBD-containing products of various types. Additional Work is Needed to Build Data on CBD Use and Safety We are encouraged by the many groups that are interested in helping to develop better data on the use and safety of CBD products, but also note that existing efforts generally are not adequate to fill the outstanding knowledge gaps.
A Practical Framework for Robust, Collaborative CBD Data Projects to Inform Public Health Decisions Here, we describe a framework for the FDA’s work in the development of research projects that lay the methodological groundwork for high quality RWD science on the safety and use of CBD products. These research projects would be aimed at building upon currently existing independent state and national quality and safety monitoring efforts, observational study data models, and novel data sources to develop more robust capabilities and methods for CBD data collection and analysis.
Amy Abernethy, M.D., Ph.D.
We know from experience that collaborative projects with researchers across government, academia, and the private sector can stimulate rapid progress in the development of rigorous methods for collecting and analyzing RWD. Most recently, in the context of COVID-19, collaborative research projects between the FDA and outside data experts have focused on using RWD to improve analytical methods and inform the public health response to the pandemic. It is important to note that there are research questions for which RWD research projects are unlikely to substitute for certain types of traditional studies. We do not expect that analyses of observational data will substitute for other types of studies in certain contexts. For example, appropriately designed animal studies can address toxicological issues that are difficult to study in humans, such as chronic, developmental, and reproductive toxicity. However, we strongly believe that RWD, when collected and analyzed using rigorous methods, can be important for moving the science forward—including by aiding hypothesis generation and by refining the design of follow-up studies. For example, RWD may identify new potential adverse events or subpopulations of CBD users that should be the focus of follow-up studies. For CBD data collection and analysis efforts to have the maximum scientific impact, they should be designed to address the most significant practical and scientific challenges in this area.
Below, we highlight challenges in current capabilities for collecting and evaluating CBD-related data and point to a framework for the FDA’s development of research projects that leverage novel data sources and can form the foundation for additional research on the safety profile of CBD products. First, we describe principles that we believe should guide this work. Guiding principles for FDA’s work in this area include the following: Research projects should contribute, where possible, to the development of more sophisticated data infrastructure for understanding the safety and quality of CBD products. Research projects should yield information that helps us refine future studies—for example, by identifying potential adverse events or subpopulations that are most important to study further. Research projects should be designed with the goal of complementing existing work by other public health agencies, such as NIH and SAMHSA, as well as other stakeholders. States provide an important laboratory for novel data collection and analysis. The FDA projects should build on existing efforts at the state and national level to incorporate data from poison control centers, emergency departments, and other potential sources of information about adverse events related to CBD products.
What is the denominator of risk for adverse events in the population taking CBD?
What specific populations have the highest CBD exposures and what specific products are frequently used?
What other products, such as over-the-counter or prescription drugs, are used alongside CBD products?
Are there risks associated with interactions between CBD products and other products, beyond those that have already been identified and communicated by the FDA?
Data collection systems may not yet have specific codes that can precisely identify specific CBD products. Longitudinal studies (i.e., studies that provide data about the health of subjects over an extended period of time) are needed to understand long-term health effects of CBD use.
Evaluate approaches to link adverse event data with CBD product sampling and testing data. Collaborate on the development and evaluation of systems and methods, such as an open, opt-in registry for users of CBD, to gain a better understanding of safety outcomes of interest and incorporate data from other sources.
Evaluate the use of market-research data and other data sources that provide insights on the use of specific CBD products in different populations. Evaluate use of data linkage approaches to provide insights about safety risks that may appear across time while protecting the privacy of patients and consumers.
Evaluate the value of combining multiple research and data approaches to synthesize an aggregate view of CBD safety and quality across the market and across time. Evaluate which strategies are best for safety and quality monitoring for different types of CBD products. The use of novel data sources to complement other scientific data (e.g., toxicology studies) will be key to providing the foundational science needed to more fully understand the safety profile of products containing CBD.
We see significant promise in small, targeted projects that improve data methods in the near-term and point to future opportunities for collecting and analyzing data on CBD products and, potentially, other types of products in the future. Resources for You: FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD) FDA and Cannabis: Research and Drug Approval Process Real-World Evidence Content current as of: 01/08/2021
Inspirational Technologies (2021)
“We Celebrate Our Individual Rights With Pride” Inspirational Technologies-2021
Thinking Outside The Pharmacy Box – CBD
You must be logged in to post a comment.